# Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients

> **NCT05109650** · PHASE1 · TERMINATED · sponsor: **Bio-Thera Solutions** · enrollment: 13 (actual)

## Conditions studied

- Advanced Solid Tumour

## Interventions

- **DRUG:** BAT6026
- **DRUG:** BAT1308

## Key facts

- **NCT ID:** NCT05109650
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-28
- **Primary completion:** 2023-03-23
- **Final completion:** 2024-02-02
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Considering that the high budget will affect the subsequent development, it is decided to terminate the test voluntarily
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05109650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05109650, "Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumour Patients". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05109650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*